Contribution of the Prosigna® (PAM50) Gene Signature Assay as a New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer

Nadia Harbeck, 1 Rachel Wuerstlein 1 and Karl Sotlar 2

Abstract

The Prosigna® Breast Cancer Prognostic Gene Signature Assay is based on the characterisation of 50 genes relevant to breast cancer biology and provides intrinsic subtype identification based on the individual tumour biology, a prognostic risk of recurrence (ROR) score and a risk group classification, for each individual patient tested. The Prosigna assay is indicated for post-menopausal women with early-stage hormone receptor-positive breast cancer with or without nodal involvement. Running on the NanoString nCounter® DX Analysis system, which allows direct digital counting of target molecules, the assay offers a simple, reproducible and reliable method to profile many genes simultaneously with high sensitivity and precision. The Prosigna Breast Cancer Prognostic Gene Signature Assay has received 510(k) clearance from the US Food and Drug Administration. It has also received a CE mark and is available for use, among other geographical areas, in the EU, Israel and parts of the Middle East, through qualified local pathology laboratories. The de-centralised testing enables timely result delivery and direct interaction between the laboratory pathologists and treating physicians. The analytical reproducibility, precision and robustness of Prosigna have been demonstrated. Moreover, it has been clinically validated in two independent prospective-retrospective studies using >2,400 samples from post-menopausal patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG 8) and Arimidex, Tamoxifen Alone or Combined (ATAC) trials (Level 1B Evidence). These validation studies show that Prosigna identifies a clinically relevant low-risk subgroup among both node-negative and node-positive patients with 1-3 involved lymph nodes. Moreover, the ROR score predicts risk of late distant recurrence as well as for high risk of local recurrence. Prosigna thus can offer clinically relevant information, which may help guide treatment decision-making in early breast cancer.

Keywords

Breast cancer, intrinsic subtypes, PAM50, risk of recurrence (ROR), analytical validation

Disclosure: Nadia Harbeck has received honoraria for lectures from NanoString and for consulting from Genomic Health. Rachel Wuerstlein has received honoraria for lectures from NanoString and Genomic Health. Karl Sotlar has received speakers’ honoraria and travel support from NanoString. The authors are grateful for the editorial assistance provided by NanoString.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.

Received: 27 May 2015 Accepted: 6 September 2015 Citation: European Oncology & Haematology, 2015;11(2):85–91. DOI: http://doi.org/10.17925/EOH.2015.11.02.85

Correspondence: Nadia Harbeck, Breast Center, University of Munich, Marchioninistraße 15, 80377 Munich, Germany. E: nadia.harbeck@med.uni-muenchen.de

Support: Editorial support for this manuscript was provided by Nanostring. The opinions expressed are those of the authors and do not necessarily reflect those of Nanostring. Final approval of the manuscript and its content rested solely with the scientific authors.

While the incidence of primary breast cancer has increased recently, most patients are diagnosed with early-stage disease and good prognosis. Around 80 % of patients with early breast cancer have estrogen receptor (ER)-positive disease and their prognosis will be improved substantially by adjuvant chemotherapy. Nevertheless, the rate of distant recurrence (DR) in these patients can be as high as >20 % in the first 10 years and this rate can be reduced by adjuvant chemotherapy.1

It is a priority in clinical breast cancer practice to differentiate patients at high risk of recurrence (ROR) from the majority at low risk (i.e. ≤10 % over 10-years) who may be spared chemotherapy.2 The diversity in breast cancer, in terms of molecular alterations, cellular composition and clinical outcome, creates a challenge for developing tumour classifications that are clinically useful for prognosis estimation.2 The heterogeneity of breast cancer can be categorised into distinct subgroups called ‘intrinsic’ subtypes that are defined by their pattern of gene expression and clinical outcome: Luminal A, Luminal B, human epidermal growth factor 2 (HER2)-enriched and basal-like.3,4 These intrinsic subtypes have been studied extensively,5,6 and the St Gallen International Expert Consensus has recognised that these intrinsic subtypes provide key information for treatment decision-making in early breast cancer.7–9

The intrinsic subtypes were first identified and long studied using genome-wide RNA expression profiling or DNA microarrays, and fresh frozen tissue. In order to identify the original intrinsic subtypes using the clinically relevant formalin-fixed paraffin-embedded (FFPE)
Breast Cancer

Figure 1: Distribution of 108 ROR Scores Measured for Each of the 5 Pooled RNA Samples

Figure 2: Average Tissue Block ROR Compared with the Individual ROR Score for All Samples in the Analytical Validation of the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System Using FFPE Breast Tumour Specimens

Prosigna Breast Cancer Prognostic Gene Signature Assay

The Prosigna assay measures a gene-expression profile using RNA extracted from FFPE breast tumour tissue. The gene-expression data are weighted together with clinicopathological variables (i.e., tumour size and number of positive nodes) to generate an intrinsic subtype and a score indicative of the probability of distant disease recurrence. The assay has been validated on the NanoString nCounter Analysis System. The report provides a risk category (low, intermediate or high), which is based on the ROR score. ROR has been shown to discriminate between high- and low-risk groups in node-negative and node-positive tamoxifen-treated patients. Prosigna ROR and risk assignment takes into account patient nodal status. As nodal status is an independent risk factor, the node-positive population has a risk curve that is shifted towards higher risk compared with the node-negative population. Therefore, to maintain similar outcomes for the risk groups between node-negative and node-positive disease, the cut-off points used for risk assignment differ between node-negative and node-positive patients.
Analytical Validation
The performance of the Prosigna Breast Cancer Prognostic Gene Signature Assay was validated on the nCounter Analysis System, across three laboratories for reproducibility, precision and robustness.\textsuperscript{13} RNA input range was validated by comparing assay results at the extremes of the specified range to the nominal RNA input level.\textsuperscript{13}

Precision Assessment
Precision was derived from 108 replicates of each of five pooled RNA samples, at three different sites, two operators at each site, each with three different reagent lots. There was 100 \% concordance between the measured subtype result and expected subtype result and 100 \% concordance between measured and expected risk category.\textsuperscript{13,16} The mean ROR difference between reagent lots on a 0–100 scale was <1 ROR unit apart across all 108 measurements for each of the five pooled breast tumour RNA samples (see Figure 1).\textsuperscript{16} The variance components analysis resulted in a total standard deviation of 0.67.\textsuperscript{16} There was no detectable site-to-site or operator-to-operator variance (<1 \% of total variance), a result that could be critical for a de-centralised test.\textsuperscript{16}

Reproducibility Assessment
Following an independent pathology review at each site, the reproducibility was assessed by testing replicate tissue sections from 43 FFPE breast tumour blocks across the three sites and nCounter platforms.\textsuperscript{13,16} The calculated test results from the 43 tissues across all sites represented (see Figure 2) a wide range of ROR scores (94 units); all risk categories; and all four intrinsic subtypes.\textsuperscript{13,16} On average, the differences between the sites were minimal (<1 \% of total variance). The variance components analysis resulted in a total standard deviation of 2.89 ROR units. The average concordances between sites were: 97 \% for intrinsic subtype classifications and 90 \% for risk classifications.

Assessment of Robustness
Non-tumour tissue was included in the test to evaluate interference and the robustness of the test to non-tumour tissue.\textsuperscript{13} The Prosigna test was robust against the inclusion of adjacent non-tumour tissue in the assay. Results were stable in the presence of moderate amounts of surrounding non-tumour tissue (maximum 70 \% by area) (see Figure 3). Results were also shown to be stable across the specified range of RNA input.

These data demonstrate that the Prosigna assay is analytically reproducible, precise and robust, even when performed at multiple test sites and including all potential process variables. Together with the clinical validation, this supporting evidence for a decentralised test led to FDA clearance (510K) in September 2013. This differentiates the new-generation Prosigna assay from other first-generation tests that are non-reproducible, precise and robust, even when performed at multiple test sites.\textsuperscript{13}

Clinical Validation
Prosigna has been clinically validated by prospectively defined analysis of two registration-quality databases, the Arimidex, Tamoxifen Alone or Combined (ATAC) trial (NCT00849030)\textsuperscript{8} and the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG 8) trial (NCT008291759)\textsuperscript{9} using a total of >2,400 patient samples. Both studies had ≥10-year median follow-up in post-menopausal women with ER-positive early-stage breast cancer treated with endocrine therapy alone. The primary objective was to validate published observations that Prosigna ROR score provides additional prognostic information over and above standard clinical variables for DR-free survival at 10 years.

In the TransATAC study, mRNA from 1,017 patients with ER-positive primary breast cancer treated with anastrozole or tamoxifen in the ATAC trial was assessed to determine the intrinsic subtype and ROR using the nCounter technology. The Prosigna ROR score was shown to provide clinically relevant prognostic information in endocrine-treated patients with ER-positive, node-negative disease.\textsuperscript{8} ROR provided prognostic information beyond the clinical treatment score (CTS) in all patients (Δ LR-χ2 = 33.9; p<0.001) and in all four subgroups: node-
Breast Cancer

Figure 5: Distant Recurrence-free Survival Kaplan–Meier Plots for PAM50 ROR Score High-, Intermediate- and Low-risk Groups with 95 % Confidence Intervals in Post-menopausal Patients of the ABCSG 8 Trial Treated with Adjuvant Endocrine Therapy Alone

As treatment decisions are the most difficult for patients classified as intermediate, precise assignment of patients to risk groups is needed. In a meta-analysis of the impact of Oncotype Dx breast cancer assay in clinical practice, nearly 40 % of patients were assigned to an intermediate risk category classification where optimal treatment is unclear.26 Ongoing prospective trials such as TAILORx (NCT00310180), RxPONDER (NCT01272037), WSG-PlanB (NCT01049425) and WSG-ADAPT26 (ADAPT Umbrella: NCT01718338; ADAPT HER2+/HR+:NCT01745965; ADAPT HER2+/HR-: NCT01817452; ADAPT TN: NCT01815242) are evaluating actual risk and optimal therapy for these intermediate-risk patients. Determining the intrinsic subtype, especially in the intermediate risk group, may also be helpful to guide clinical decision-making.27

Prosigina was further validated as a reliable prognostic indicator for DR-free survival (DRFS) in hormone receptor-positive, post-menopausal patients from the ABCSG 8 trial.19 ABCSG 8 was first designed to evaluate the clinical efficacy of tamoxifen versus anastrozole after 2 years of tamoxifen in >3,700 patients. A translational study of the ABCSG 8 was conducted with 1,478 FFPE blocks available. ABCSG 8 patients were post-menopausal women treated with adjuvant systemic endocrine therapy alone in the form of 5 years of tamoxifen or 2 years of tamoxifen and 3 years of anastrozole. Prosigina ROR scores significantly added prognostic value to the clinical predictor (p<0.0001) in all tested subgroups. Within all tested subgroups, significant and clinically relevant discrimination was demonstrated between low- and high-risk groups (see Figure 5). The Luminal A intrinsic subtype cohort had a significantly lower ROR at 10 years compared with Luminal B tumours (p<0.0001) (see Figure 6). The 10-year metastasis risk in the ROR low-risk category for all patients combined (i.e. node-positive and node-negative) was <3.5 %.

The results of this analysis, which are concordant with the results of the analysis from the ATAC trial,5 constitute Level 1B evidence for clinical validity of the PAM50 test for predicting the risk of DR in post-menopausal women with ER-positive early breast cancer (see Table 1). The absolute risk of DR of <3.5 % by year 10 in the low-risk population means that adjuvant chemotherapy would have approximately 1 % absolute benefit, so such patients could be spared unwarranted over-treatment that could result in a similar risk of serious adverse events.28 The test also identified a low-risk subgroup within node-positive patients. There is a clear difference in outcomes for Luminal A compared with Luminal B subtypes, which may also be valuable clinical information.29

More recently, combined analysis of the two pivotal trials, ABCSG 8 and ATAC, demonstrated that the PAM50-derived ROR, ROR risk groups and intrinsic subtypes provide reliable prognostic information for metastasis risk in addition to and beyond established clinicopathological factors in node-positive hormone receptor-positive breast cancer.20 In this large dataset (543 node-negative patients), low- and high-risk patients were accurately discerned. RNA from paraffin blocks was analysed using the PAM50 test and the primary objective was to investigate the prognostic information provided by the ROR score added to combined clinical standard variables, using log-likelihood tests. At a median follow-up of 6.6 years, distant metastases occurred in 97 (18 %) of the 543 node-negative patients. The 10-year DR risk was increased significantly in the high-risk group compared with the low-risk group derived from ROR score for one-positive node (25.5 %, 95 % confidence interval [CI] 17.5–36.1 % versus 6.6 %, 95 % CI 3.3 %–12.8 %) and compared with the combined low/intermediate risk group for patients with two or three positive nodes (33.7 %, 95 % CI 25.5–43.8 % versus 12.5 %, 95 % CI 6.6–22.8 %). Further, the Luminal A intrinsic subtype was associated with significantly lower negative, node-positive, HER2-negative and HER2-negative/node-negative; more information was added by ROR than by Oncotype Dx® recurrence score (RS). Concordance indices in the HER2-negative/node-negative subgroup were 0.670, and 0.769 for RS, and ROR, respectively. Furthermore, ROR displayed improved discrimination of intermediate- and higher-risk groups compared with RS. More patients were scored as high risk and fewer as intermediate risk by ROR than by RS (see Figure 4).

Table 1

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>10-year DRFS (95 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminal A</td>
<td>1,004</td>
</tr>
<tr>
<td>Luminal B</td>
<td>418</td>
</tr>
<tr>
<td>Luminal A</td>
<td>1,004</td>
</tr>
<tr>
<td>Luminal B</td>
<td>418</td>
</tr>
<tr>
<td>Luminal A</td>
<td>1,004</td>
</tr>
<tr>
<td>Luminal B</td>
<td>418</td>
</tr>
<tr>
<td>Luminal A</td>
<td>1,004</td>
</tr>
<tr>
<td>Luminal B</td>
<td>418</td>
</tr>
</tbody>
</table>

CI = confidence interval; DRFS = distant recurrence-free survival; HR = hazard ratio. Reproduced with permission from Gnant et al., 2014.17

Figure 6: Disease Recurrence-free Survival Kaplan–Meier Plots for PAM50 Luminal A and B Subtypes with 95 % Confidence Interval

As treatment decisions are the most difficult for patients classified as intermediate, precise assignment of patients to risk groups is needed. In a meta-analysis of the impact of Oncotype Dx breast cancer assay in clinical practice, nearly 40 % of patients were assigned to an intermediate risk category classification where optimal treatment is unclear.26 Ongoing prospective trials such as TAILORx (NCT00310180), RxPONDER (NCT01272037), WSG-PlanB (NCT01049425) and WSG-ADAPT26 (ADAPT Umbrella: NCT01718338; ADAPT HER2+/HR+:NCT01745965; ADAPT HER2+/HR-: NCT01817452; ADAPT TN: NCT01815242) are evaluating actual risk and optimal therapy for these intermediate-risk patients. Determining the intrinsic subtype, especially in the intermediate risk group, may also be helpful to guide clinical decision-making.27

Prosigina was further validated as a reliable prognostic indicator for DR-free survival (DRFS) in hormone receptor-positive, post-menopausal patients from the ABCSG 8 trial.19 ABCSG 8 was first designed to evaluate the clinical efficacy of tamoxifen versus anastrozole after 2 years of tamoxifen in >3,700 patients. A translational study of the ABCSG 8 was conducted with 1,478 FFPE blocks available. ABCSG 8 patients were post-menopausal women treated with adjuvant systemic endocrine therapy alone in the form of 5 years of tamoxifen or 2 years of tamoxifen and 3 years of anastrozole. Prosigina ROR scores significantly added prognostic value to the clinical predictor (p<0.0001) in all tested subgroups. Within all tested subgroups, significant and clinically relevant discrimination was demonstrated between low- and high-risk groups (see Figure 5). The Luminal A intrinsic subtype cohort had a significantly lower ROR at 10 years compared with Luminal B tumours (p<0.0001) (see Figure 6). The 10-year metastasis risk in the ROR low-risk category for all patients combined (i.e. node-positive and node-negative) was <3.5 %.

The results of this analysis, which are concordant with the results of the analysis from the ATAC trial,5 constitute Level 1B evidence for clinical validity of the PAM50 test for predicting the risk of DR in post-menopausal women with ER-positive early breast cancer (see Table 1). The absolute risk of DR of <3.5 % by year 10 in the low-risk population means that adjuvant chemotherapy would have approximately 1 % absolute benefit, so such patients could be spared unwarranted over-treatment that could result in a similar risk of serious adverse events.28 The test also identified a low-risk subgroup within node-positive patients. There is a clear difference in outcomes for Luminal A compared with Luminal B subtypes, which may also be valuable clinical information.29

More recently, combined analysis of the two pivotal trials, ABCSG 8 and ATAC, demonstrated that the PAM50-derived ROR, ROR risk groups and intrinsic subtypes provide reliable prognostic information for metastasis risk in addition to and beyond established clinicopathological factors in node-positive hormone receptor-positive breast cancer.20 In this large dataset (543 node-negative patients), low- and high-risk patients were accurately discerned. RNA from paraffin blocks was analysed using the PAM50 test and the primary objective was to investigate the prognostic information provided by the ROR score added to combined clinical standard variables, using log-likelihood tests. At a median follow-up of 6.6 years, distant metastases occurred in 97 (18 %) of the 543 node-negative patients. The 10-year DR risk was increased significantly in the high-risk group compared with the low-risk group derived from ROR score for one-positive node (25.5 %, 95 % confidence interval [CI] 17.5–36.1 % versus 6.6 %, 95 % CI 3.3 %–12.8 %) and compared with the combined low/intermediate risk group for patients with two or three positive nodes (33.7 %, 95 % CI 25.5–43.8 % versus 12.5 %, 95 % CI 6.6–22.8 %). Further, the Luminal A intrinsic subtype was associated with significantly lower negative, node-positive, HER2-negative and HER2-negative/node-negative; more information was added by ROR than by Oncotype Dx® recurrence score (RS). Concordance indices in the HER2-negative/node-negative subgroup were 0.670, and 0.769 for RS, and ROR, respectively. Furthermore, ROR displayed improved discrimination of intermediate- and higher-risk groups compared with RS. More patients were scored as high risk and fewer as intermediate risk by ROR than by RS (see Figure 4).
risk of DR compared with the luminal B subtype in patients with one positive node and in patients with two or three positive nodes.

Late Recurrence for Estrogen Receptor-positive Breast Cancer
The prediction and prevention of late breast cancer recurrence is an important and largely unmet need and remains a major clinical challenge. Indeed, despite recent improvements in breast cancer treatment, some women with ER-positive early-stage breast cancer remain at risk of DR beyond the first 5 years following diagnosis. Multiple clinical trials have shown that the risk of late DR may be reduced by extending adjuvant endocrine therapy beyond 5 years. Identifying newly diagnosed women with ER-positive breast cancer at high risk of having their cancer recur between 5 and 10 years after diagnosis is a priority to help oncologists to make more informed treatment decisions.

Adjuvant chemotherapy and endocrine therapy for early breast cancer have had a positive impact on outcomes; however, the annual rate of late recurrence is still 2% for >15 years, even after 5 years of tamoxifen therapy. The value of three breast cancer assay score models was assessed in predicting the risk of DR in years 5 to 10: the PAM50 gene signature, the Oncotype DX Breast Cancer RS and the immunohistochemical marker (IHC4) score, were included. The IHC4 score, which may be subject to large inter- and intra-observer variability, was originally derived from a centralised IHC assessment of ERs, progesterone receptors (PR), HER2 and Ki67 expression in the TransATAC cohort.

A total of 940 samples from the TransATAC dataset were included in this study. RS and ROR were assessed from RNA extracted from tumour samples by Genomic Health, Inc. for validation of the Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence after Endocrine Therapy. Reproduced with permission from Sestak et al., 2013.

Table 1: Prognostic Factors in Early Breast Cancer – AGO Guidelines

<table>
<thead>
<tr>
<th>Prognostic Factors iii in Early Breast Cancer Factor</th>
<th>LoE2007</th>
<th>CTS</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disseminated tumour cells (DTC, in bone marrow)</td>
<td>I</td>
<td>B</td>
<td>+/–</td>
</tr>
<tr>
<td>Circulating tumour cells (CTC, in blood, Cell Search®)</td>
<td>I</td>
<td>B</td>
<td>+/–</td>
</tr>
<tr>
<td>Therapy decisions based on CTC phenotypes</td>
<td>III</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td>Multigene assay (EndoPredict®, Prosigna®)</td>
<td>I</td>
<td>B</td>
<td>+/–</td>
</tr>
<tr>
<td>Oncotype DX® (NO-1 ER+ HER2-)</td>
<td>I</td>
<td>B</td>
<td>+/–</td>
</tr>
<tr>
<td>70 gene signature (MammaPrint®, NO-1)</td>
<td>II</td>
<td>C</td>
<td>+/–</td>
</tr>
<tr>
<td>IHC4 (central pathology, published algorithm)</td>
<td>I</td>
<td>B</td>
<td>+/–</td>
</tr>
</tbody>
</table>

*Should only be used in selected patients if all other criteria are inconclusive for therapeutic decision-making. Validated clinical data only available for this assay. *Cuzick et al., J Clin Oncol, 2011,29(42)-6; Levels of evidence (LoE) 2009 criteria; $Validated clinical data only available for this assay; #Cuzick et al., J Clin Oncol, 2011,29(42)-6; Levels of evidence (LoE) 2009 criteria; ± should only be used in selected patients if all other criteria are inconclusive for therapeutic decision-making.

The Arbeitsgemeinschaft Gynäkologische Onkologie IV (AGO) grades of recommendation include: + this investigation or therapeutic intervention is of limited benefit for patients and can be performed, +/– this investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases. According to current knowledge a general recommendation cannot be given; – this investigation or therapeutic intervention can be of disadvantage for patients and might not be performed. CTS = clinical treatment score; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemical marker (IHC4). Reproduced with permission from Professor Anton Scharl.

Late Recurrence after Endocrine Therapy
Figure 7: Prosigna ROR Score versus Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence after Endocrine Therapy

<table>
<thead>
<tr>
<th>Figure 7A：Prosigna ROR Score versus Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence after Endocrine Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 7B：Prosigna ROR Score versus Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence after Endocrine Therapy</td>
</tr>
</tbody>
</table>

Annual hazard rate curves (II) for distant recurrence according to risk group and scores (all split at the median). A. Nodal status and tumour size are major prognostic indicators of both early and late recurrence. B. Prosigna risk of recurrence (ROR) risk groups widen separation of hazards for death beyond 5 years compared with immunohistochemical markers (IHC4) and Oncotype DX. RS = recurrence score. Reproduced with permission from Sestak et al., 2013.

The PAM50 ROR score and ROR-based risk groups have also been shown to provide significant additional prognostic information in terms of late DRFS compared with a combined score of clinical factors alone in the ABCSG 8 study. Between years 5 and 15, the observed absolute risk of DR was 2.4% in the low ROR-based risk group compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease. These results indicate that the PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late DR beyond what can be achieved with established clinicopathological factors.

The ROR score may thus also be useful in identifying women who are at high risk of late recurrence and who may benefit from either more intensive treatment (chemotherapy) or extended endocrine treatment, beyond 5 years.
Breast Cancer

versus tamoxifen following anastrozole post-surgery were analysed blocks from 1,308 patients from the ABCSG 8 trial comparing tamoxifen 10-year LRFS) and Luminal B cancer (95.9 % 10-year LRFS; p=0.022). showed a significant difference in LRFS comparing Luminal A (98.1 % 10-year LRFS; p=0.0005). Biological subtype analysis also by the PAM50 assay. The Cox regression model revealed that the ROR Local Recurrence for Estrogen Receptor-positive Breast Cancer

The PAM50 ROR score and intrinsic subtype have been demonstrated to be independent predictors of local recurrence-free survival (LDFS). Tumour blocks from 1,308 patients from the ABCSG 8 trial comparing tamoxifen versus tamoxifen following anastrozole post-surgery were analysed by the PAM50 assay. The Cox regression model revealed that the ROR score significantly predicted LDFS independent of nodal status, tumour size and age (p=0.0081). Patients assigned to the high-risk category (ROR >57) had a LDFS of 94.4 % whereas low-risk patients (ROR <57) showed a 98.4 % 10-year LDFS (p=0.0008). Biological subtype analysis also showed a significant difference in LDFS comparing Luminal A (98.1 % 10-year LDFS) and Luminal B cancer (95.9 % 10-year LDFS; p=0.022).

Decision Impact Studies

There are three European decision impact (DI) studies: one (France; multicentre) in progress and two (Spain; GEICAM group; Germany; West German Study Group) that have already been completed.

The three studies aimed at recruiting 200 patients each and the protocols are identical. The aim is to examine whether the Prosinga test influences physician and patient adjuvant treatment selection beyond standard local IHC testing. A meta-analysis of the three studies is planned to yield a larger DI database. The Spanish GEICAM decision impact study showed that Prosinga indeed influenced adjuvant-therapy recommendations.33 Prosinga changed treatments in 20 % of patients. For 22 (11 %), the initial recommendation was changed from chemotherapy and hormonal therapy to hormonal therapy alone and for 18 (9 %), from hormonal therapy to chemotherapy and hormonal therapy. Further, Prosinga increased physician confidence in prognosis and in recommended treatments while patient anxiety was reduced. Initial results from the German DI Study indicate rather similar results with a change in treatment choice of 18.2 % after obtaining the Prosinga results.34 Final results of the German DI study will be reported by the end of 2015. An interim quality assurance analysis from the German DI study showing excellent reproducibility in the first 71 samples between two routine laboratories is depicted in Figure 8.

Table 2: Main Features of the Prosigna Breast Cancer Prognostic Gene Signature Assay

| Methodology | - In vitro diagnostic assay using the gene-expression profile of the breast cancer tissue to assess the intrinsic subtype (Luminal A, Luminal B, HER2-enriched or basal-like) and a patient’s 10-year distant ROR
- The NanoString nCounter Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of mRNA transcripts using the following steps:
  1. Hybridisation of the RNA to fluorescent Reporter Probes and Capture Probes;
  2. Purification of the target/probe complexes using nCounter Prep Plates containing reagents necessary for post-hybridisation processing and immobilisation onto the nCounter Cartridge on the nCounter Prep Station; and
  3. Analysis of the nCounter Cartridge on the nCounter Digital Analyzer to provide a test result.
- Assay measures the gene-expression profile using RNA extracted from FFPE breast tumour tissue.
- The gene-expression data are weighted together with clinicopathological variables to generate both an intrinsic subtype and a score indicative of the risk of distant recurrence of disease according to tumour size and nodal status.

| Approval | - FDA 510(k) clearance (2013)
- CE mark (2012)

| Clinical information | - Intrinsic subtype identification per patient (i.e. individualised)
- ROR – an individual score calculating a patient’s 10-year probability of disease recurrence based on the gene-expression pattern and clinicopathological criteria (i.e., tumour size, nodal status)
- Risk group classification (low [<10 %]; intermediate–high [>20 %])

| Patient subgroup | - Female patients with early breast cancer who have undergone either mastectomy or breast-conserving therapy in conjunction with locoregional treatment consistent with standard of care, either as:
  1. A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with HR+, lymph node-negative, stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors
  2. A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with HR+, lymph node-positive (1–3 positive nodes), stage II or IIIA breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors

FDA = US Food and Drug Administration; FFPE = formalin-fixed paraffin-embedded; HR+ = hormone receptor-positive; ROR = risk of recurrence.

Local Recurrence for Estrogen Receptor-positive Breast Cancer

The PAM50 ROR score and intrinsic subtype have been demonstrated to be independent predictors of local recurrence-free survival (LDFS). Tumour blocks from 1,308 patients from the ABCSG 8 trial comparing tamoxifen versus tamoxifen following anastrozole post-surgery were analysed by the PAM50 assay. The Cox regression model revealed that the ROR score significantly predicted LDFS independent of nodal status, tumour size and age (p=0.0081). Patients assigned to the high-risk category (ROR >57) had a LDFS of 94.4 % whereas low-risk patients (ROR <57) showed a 98.4 % 10-year LDFS (p=0.0008). Biological subtype analysis also showed a significant difference in LDFS comparing Luminal A (98.1 % 10-year LDFS) and Luminal B cancer (95.9 % 10-year LDFS; p=0.022).

Decision Impact Studies

There are three European decision impact (DI) studies: one (France; multicentre) in progress and two (Spain; GEICAM group; Germany; West German Study Group) that have already been completed.
Conclusions

The Prosigna assay is based on the PAM50 gene signature. It indicated for post-menopausal women with early-stage ER-positive/Her2-negative breast cancer with or without axillary lymph node involvement (main features are summarised in Table 2). It has been demonstrated to be analytically reproducible, precise and robust and has been independently clinically validated. The Prosigna assay was approved by the majority of the panel at the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 for its prognostic strength for early years (1-5) as well as later years (5-10) recurrences.12

In a prospectively planned retrospective comparison of the Prosigna, the Oncotype Dx Breast Cancer Assay and the iHC4 score, the Prosigna ROR score provided the strongest prognostic information regarding risk of DR in 5 to 10 years following diagnosis in post-menopausal ER-positive early-stage breast cancer patients treated with 5 years of endocrine therapy.13 Separate analysis of the PAM50 ROR score for prediction of DR and late DR (beyond 5 years after diagnosis and treatment) in 1,478 post-menopausal patients from the ABCSG 8 trial also validated the test for these endpoints after a median follow up of 11 years.14

The Prosigna ROC score differentiates patients with post-menopausal, endocrine responsive breast cancer in terms of their risk of recurrence, and physicians can stratify patients into overall risk categories with different prognoses. The Prosigna assay can also be used to assign intrinsic subtypes to all cases and DRFS is significantly different between Luminal A and Luminal B subtypes. In the combined analysis, 15-year late DRFS was 92.8 % for the Luminal A and 86.2 % for the Luminal B group. The prognostic differences between Luminal A and Luminal B intrinsic subtypes were less pronounced compared with that between the ROR low- and high-risk groups.15

The Prosigna ROR also identifies patients at high risk of local recurrence.16 Last but not least, DI evidence has provided additional data showing that the Prosigna assay has clinical utility in the real-world setting, its application seems to be associated with at least a 20 % change in treatment decisions. Additional ongoing DI studies will provide real-world data in various healthcare settings with regard to analytical validity, change of treatment decisions as well as health economic analyses. In view of its broad database in terms of prognostic estimation and intrinsic subtyping in post-menopausal patients, an open clinical question that needs to be addressed for the Prosigna assay is certainly its validation for pre-menopausal patients.

Overall, the Prosigna assay may enable clinicians to make more informed treatment choices for women with endocrine responsive breast cancer by determining the intrinsic subtype as well as short- and long-term ROR. This may help to identify women who may be spared adjuvant chemotherapy or who may benefit from extended adjuvant endocrine therapy.